18 unchanged sentences
Other Information
+Added: Director and Officer Trading Arrangements
+Added: During the three months ended December 31, 2023, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
26 unchanged sentences
4.5 Warrant to Purchase Common Stock, dated March 30, 2021 (incorporated by reference to Exhibit 10.6.2 to Humacyte, Inc.’s Registration Statement on S–4/A, filed with the SEC on June 14, 2021).
−Removed: 4.6 Description of the Company’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.6 to Humacyte, Inc.’s Annual Report on Form 10-K filed with the SEC on March 29, 2022 ) .
+Added: Description of the Company’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.
+Added: 10.1.1 Revenue Interest Purchase Agreement, dated as of May 12, 2023, by and among Humacyte Global, Inc., Humacyte, Inc.
+Added: and Hook SA LLC.
+Added: (incorporated by reference to Exhibit 10.1 to Humacyte, Inc.’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023).
+Added: 10.1.2!* Waiver, dated as of February 18, 2024, by and among Humacyte Global, Inc., Humacyte, Inc.
+Added: and Hook SA LLC.
+Added: 10.2 Option Agreement, dated as of May 12, 2023, by and among Humacyte, Inc., TPC Investments III LP and TPC Investments Solutions LP.
+Added: (incorporated by reference to Exhibit 4.1 to Humacyte, Inc.’s Registration Statement on Form S-3, filed with the SEC on June 9, 2023).
10.3 Open Market Sale Agreement, dated September 1, 2022, by and between Humacyte, Inc.
1 unchanged sentence
333-267225), filed with the SEC on September 1, 2022).
−Removed: 10.2 Loan and Security Agreement, dated March 30, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P.
−Removed: and Humacyte Global, Inc.
−Removed: (incorporated by reference to Exhibit 10.6 to Humacyte, Inc.’s Registration Statement on S–4/A, filed with the SEC on June 14, 2021).
−Removed: 10.2.1 First Amendment to Loan and Security Agreement, dated June 30, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P.
−Removed: and Humacyte Global, Inc.
−Removed: (incorporated by reference to Exhibit 10.6.1 to Humacyte, Inc.’s Registration Statement on S–4/A, filed with the SEC on July 23, 2021).
−Removed: 10.2.2 Second Amendment to Loan and Security Agreement, dated as of September 17, 2021, by and among Humacyte, Inc., Humacyte Global, Inc., Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.
−Removed: (incorporated by reference to Exhibit 10.2.2 to Humacyte, Inc.’s Registration Statement on Form S–1, filed with the SEC on September 17, 2021).
Distribution Agreement, dated June 25, 2018, by and between Fresenius Medical Care Holdings, Inc.
42 unchanged sentences
10.12+ Executive Employment Agreement, dated May 18, 2021, between Dale Sander and Humacyte, Inc.
−Removed: Executive Employment Agreement, effective as of April 4, 2022 between Shamik Parikh, MD and Humacyte , Inc.
+Added: (incorporated by reference to Exhibit 10.11 to Humacyte, Inc.’s Annual Report on Form 10-K, filed with the SEC on March 24, 2023).
+Added: 10.13+ Executive Employment Agreement, dated September 13, 2019 between Heather Prichard, Ph.D.
+Added: and Humacyte Global, Inc.
+Added: (incorporated by reference to Exhibit 10.16 to Humacyte, Inc.'s Registration Statement on S-4, filed with the SEC on March 23, 2021).
10.14+ Humacyte, Inc.
53 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Humacyte, Inc.
+Added: Compensation Clawback Policy.
The following materials from Humacyte, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL (Inline eXtensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets as of December 31, 2022 and 2021, (ii) Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021, (iii) Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the years ended December 31, 2022 and 2021, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021, and (v) Notes to Consolidated Financial Statements.
+Added: (i) Consolidated Balance Sheets as of December 31, 2023 and 2022, (ii) Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022, (iii) Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022, and (v) Notes to Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
18 unchanged sentences
(Principal Financial and Accounting Officer) March 28, 2024
−Removed: Director March 24, 2023
+Added: /s/ Kathleen Sebelius Director March 28, 2024
Kathleen Sebelius
−Removed: Director March 24, 2023
+Added: /s/ Gordon M.
+Added: Binder Director March 28, 2024
Director March 28, 2024
14 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.